ATG4B and breast cancer: The rationale that ATG4 proteins might be therapeutic targets mostly stems from the fact that these proteins are highly over-expressed in some cancer types compared to non-cancerous cells (Costa et al., 2016) and genetic inhibition of ATG4B either through siRNA or use of a dominant negative form of the gene show some benefit in chronic myeloid leukemia (Rothe et al., 2014), breast cancer (Bortnik et al., 2016) and pancreatic carcinoma (Yang et al., 2018).